Prognostic value of obtaining a complete hematologic response at 6 months for both treatment groups. The numbers of patients from whom data were available to calculate the hematologic response at 6 months ±4 weeks after randomization are given. Survival is calculated after a landmark analysis at 6 months. Curves are based on the intention to treat, regardless of any protocol violation or cause of death. Data on those patients that underwent BMT during chronic phase were censored as of the date of transplantation.